In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SteadyMed Ltd.

http://www.steadymed.com

Latest From SteadyMed Ltd.

Keeping Track Of US FDA Decisions: Approvals For Ongentys And New Keytruda, Darzalex Dosing, But Not For Trevyent

The latest US FDA approval decision news and highlights from the Pink Sheet’s FDA Performance Tracker

US FDA Performance Tracker Drug Review

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

US FDA Performance Tracker Drug Approval Standards

Keeping Track: US FDA Approvals For Ibsrela, Gvoke And Nucala; A BTD For Tepotinib

The latest drug development news and highlights from our US FDA Performance Tracker. 

US FDA Performance Tracker Approvals

Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate

With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.

Deals Commercial
See All

Company Information

  • Other Names / Subsidiaries
    • SteadyMed Therapeutics, Inc.
UsernamePublicRestriction

Register